Aptinyx has filed a patent for compounds that can modulate NMDA receptor activity, potentially treating depression and related disorders. The patent also includes orally delivered and intravenous formulations of these compounds. GlobalData’s report on Aptinyx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aptinyx Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aptinyx, Human telomerase RT biomarker was a key innovation area identified from patents. Aptinyx's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230312591A1) describes a compound and its various forms and applications. The compound is represented by a specific chemical structure. The patent claims include different variations of the compound, such as when a certain parameter (q) is equal to 1 or 0, or when another parameter (r) is equal to 2. Additionally, the patent claims describe the compound when certain substituents (X and Y) are present in the structure.

The patent also includes claims for a specific compound represented by a different chemical structure. These claims specify different possibilities for a substituent (R1), such as when it is a specific alkyl group or when it is hydrogen. The claims further mention specific examples of R1, including tert-butyloxycarbonyl.

Furthermore, the patent claims describe the compound when another substituent (R3) is present, and provide a list of possible options for R3.

The patent also includes a claim for a compound selected from tables provided in Example 2 and Example 4, along with their pharmaceutically acceptable salts or stereoisomers. This suggests that the patent covers specific compounds listed in these tables.

Additionally, the patent claims cover a pharmaceutical composition comprising the compound described in claim 1, along with a pharmaceutically acceptable excipient. This indicates that the compound can be formulated into a pharmaceutical product.

The patent also mentions a method of treating various medical conditions, including depression, Alzheimer's disease, attention deficit disorder, schizophrenia, or anxiety. The method involves administering a therapeutically effective amount of the compound described in claim 1 to a patient in need of treatment.

In summary, the filed patent describes a compound and its various forms, along with their potential applications in pharmaceutical compositions and the treatment of certain medical conditions. The patent claims cover different variations of the compound, as well as specific examples of substituents and their combinations.

To know more about GlobalData’s detailed insights on Aptinyx, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies